Bextra "Likely" To Add Black Box Warning, Pfizer Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer expects that resolution of labeling discussions with FDA will include boxed warning about skin reactions. FDA will have to consider whether to handle issue in context of broader COX-2 class safety review.